Clients are invited to join Certara at this two-day event to further explore and connect on the future of drug development
RADNOR, PA – OCTOBER 24, 2024 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in model-informed drug development, today announced that it is continuing to scale its premier client summit Certainty in Europe. Prior Certainty events have happened in the US and Asia-Pacific regions. Certainty EU will take place in Germany on October 29-30, 2024.
“Connecting with clients and partners around the globe is pivotal to how we continue advancing our mission of transforming drug discovery and development. We’re creating spaces where likeminded drug developers discuss success stories, opportunities, and challenges so together we can deliver products, solutions, and expertise that truly make a difference,” said William F. Feehery, CEO of Certara.
Certara is offering exclusive access to its experts and industry peers to network and innovate on advancing drug development and discovery with technology. Designed with pharmacometricians, clinical pharmacologists, regulatory science professionals, biostatisticians, and data scientists in mind, the event will explore where model-informed drug development is headed along with unique customer case studies, insights, best practices and more. Featured sessions include:
- Delivering Greater Certainty to Drug Development from Molecule to Market with Certara
Featuring William Feehery, PhD, CEO, Certara - Medicines that Matter: How Biosimulation Supported FDA Approval for Duchenne Muscular Dystrophy Treatment in Children
Featuring Francesco Bellanti, Sr. Director, Certara, & Paolo Bettica, MD, PhD, CMO, Italfarmaco
- Impact of Model-Informed Drug Development on Strategic Decision Making
Featuring Piet Van Der Graaf, PharmD, PhD, SVP, Certara; Andreas Wallnofer, Pharma & Biotech executive & Simon Westbrook, PhD, CSO, Levicept Ltd
- Speeding Time to Insights with Digital Data Flow, Automation and Analytics
A panel discussion featuring Esther Vock, PhD, Director, Global Nonclinical Safety & DMPK, Boehringer Ingelheim, and Matthieu Chaton, Team Lead, Data Quality, UCB
- Generative AI for Regulatory Writing and the Impact of Generative AI for Insight Generation in Nonclinical Development
featuring Nick Brown, Global Portfolio Leader, Certara, and Thibault Geoui, PhD, MBA, Charles River Laboratories
The event continues for further exploration for in-depth community discussions for Certara’s core product offerings and solution suites:
- Pinnacle 21 clinical data management and automation suite,
- Phoenix pharmacokinetic/pharmacodynamic analysis platform, and
- Model-informed drug development for pre-clinical and clinical development.
The tracks will allow customers to learn directly from product owners about what’s new, customer stories, and the roadmaps heading into 2025.
For more information about Certainty Europe, please visit: http://certainty.certara.com/agenda-europe.
サターラについて
サターラは、独自のバイオシミュレーションソフトウェア、テクノロジー、コンサルティングサービスを通して、従来の創薬・医薬品開発に変革をもたらすことをミッションとしています。2,300社の製薬企業、主要学術機関、世界各国の規制当局がサターラのソフトウェアやコンサルティングサービスを利用しております。（70か国にてビジネス展開）Visit us at www.certara.com.
お問合せ先
Sheila Rocchio
sheila.rocchio@certara.com
報道機関の皆様：
赤津笑美 (emi.akatsu@certara.com)
PAN Communications
certara@pancomm.com
